Soundbites: Cost-Effectiveness Analysis
Scan brief descriptions of cost-effectiveness analyses conducted by our center community and our decision science colleagues across the globe.
Scaling Cancer Prevention
This analysis used decision analytic modeling to estimate the health impact, costs, and cost-effectiveness of scaling-up HPV vaccination and cervical cancer screening in 50 low- and lower-middle-income countries.
Investment Case for TB Vaccines
CHDS postdoctoral fellow Allison Portnoy and CHDS faculty Nick Menzies led economic analyses for a World Health Organization (WHO) report that describes the full value proposition for new tuberculosis (TB) vaccines.
Interventions that impose costs per DALY averted less than 3x and 1x GDP per capita are considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of this threshold.
Postdoctoral fellow Nathaniel Hendrix and CHDS’ Stéphane Verguet developed a novel method to help decision-makers in low- and middle-income countries include the risk of medical impoverishment in healthcare priority-setting.
Immunization policymakers at global and local levels need to establish priorities among new vaccines competing for limited resources. This study provides early insight into how the comparative impact of two new vaccines could be assessed in resource-poor settings with respect to affordability, cost-effectiveness, and distributional equity.